Castrate-resistant Prostate Cancer (CRPC) Market

DelveInsight's "Castrate-resistant Prostate Cancer (CRPC) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Castrate-resistant Prostate Cancer (CRPC), historical and forecasted epidemiology as well as the Castrate-resistant Prostate Cancer (CRPC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Castrate-resistant Prostate Cancer (CRPC) market report provides current treatment practices, emerging drugs, Castrate-resistant Prostate Cancer (CRPC) market share of the individual therapies, current and forecasted Castrate-resistant Prostate Cancer (CRPC) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Castrate-resistant Prostate Cancer (CRPC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Castrate-resistant Prostate Cancer (CRPC) market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Castrate-resistant Prostate Cancer Prevalence

Castrate-resistant Prostate Cancer (CRPC) Disease Understanding and Treatment Algorithm

The DelveInsight’s Castrate-resistant Prostate Cancer (CRPC) market report gives a thorough understanding of the Castrate-resistant Prostate Cancer (CRPC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Castrate-resistant Prostate Cancer (CRPC) Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Castrate-resistant Prostate Cancer (CRPC).

Castrate-resistant Prostate Cancer (CRPC) Treatment

It covers the details of conventional and current medical therapies available in the Castrate-resistant Prostate Cancer (CRPC) market for the treatment of the condition. It also provides Castrate-resistant Prostate Cancer (CRPC) treatment algorithms and guidelines in the United States, Europe, and Japan.

Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ Castrate-resistant Prostate Cancer Treatment Drugs

Castrate-Resistant Prostate Cancer (CRPC) Recent Developments

• In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx® and atezolizumab in mCRPC showed a non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.
• In September 2024, Foundation Medicine received FDA approval for FoundationOne®CDx and Liquid CDx as companion diagnostics for Lynparza® in BRCA-mutated mCRPC.
• In July 2024, the ARANOTE trial showed that NUBEQA® plus ADT significantly improved radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).
• In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for metastatic castrate-resistant prostate cancer (mCRPC).
• In June 2024, Kangpu Biopharmaceuticals received FDA approval for a Phase II/III trial of KPG-121 with Abiraterone for mCRPC.
• In May 2024, Fusion Pharmaceuticals began the Phase 2 AlphaBreak trial of FPI-2265 in mCRPC patients.
• In April 2024, Astellas Pharma received European approval for XTANDI™ in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC).
• In April 2024, FibroGen announced positive Phase 1 trial data for FG-3246 in mCRPC.

Castrate-resistant Prostate Cancer (CRPC) Epidemiology 

The Castrate-resistant Prostate Cancer (CRPC) epidemiology section provides insights about the historical and current Castrate-resistant Prostate Cancer (CRPC) patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Castrate-resistant Prostate Cancer (CRPC) market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Castrate-resistant Prostate Cancer (CRPC) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Castrate-resistant Prostate Cancer (CRPC) Epidemiology

The epidemiology segment also provides the Castrate-resistant Prostate Cancer (CRPC) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Get More Insights of this Report @ Prostate Cancer Treatment Market Size

Castrate-resistant Prostate Cancer (CRPC) Drug Chapters

The drug chapter segment of the Castrate-resistant Prostate Cancer (CRPC) report encloses the detailed analysis of Castrate-resistant Prostate Cancer (CRPC) marketed drugs and late-stage (Phase-III and Phase-II) Castrate-resistant Prostate Cancer (CRPC) pipeline drugs. It also helps to understand the Castrate-resistant Prostate Cancer (CRPC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Castrate-resistant Prostate Cancer (CRPC) Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Castrate-resistant Prostate Cancer (CRPC) treatment.

Castrate-resistant Prostate Cancer (CRPC) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Castrate-resistant Prostate Cancer (CRPC) treatment.

Castrate-resistant Prostate Cancer (CRPC) Market Outlook

The Castrate-resistant Prostate Cancer (CRPC) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Castrate-resistant Prostate Cancer (CRPC) market trends by analyzing the impact of current Castrate-resistant Prostate Cancer (CRPC) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Castrate-resistant Prostate Cancer (CRPC) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Castrate-resistant Prostate Cancer (CRPC) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Castrate-resistant Prostate Cancer (CRPC) market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Castrate-resistant Prostate Cancer (CRPC) market in 7MM.

The United States Market Outlook

This section provides the total Castrate-resistant Prostate Cancer (CRPC) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Castrate-resistant Prostate Cancer (CRPC) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Castrate-resistant Prostate Cancer (CRPC) market size and market size by therapies in Japan is also mentioned.

Castrate-resistant Prostate Cancer (CRPC) Drugs Uptake

This section focuses on the rate of uptake of the potential Castrate-resistant Prostate Cancer (CRPC) drugs recently launched in the Castrate-resistant Prostate Cancer (CRPC) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Castrate-resistant Prostate Cancer (CRPC) market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Castrate-resistant Prostate Cancer (CRPC) Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Castrate-resistant Prostate Cancer (CRPC) market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Castrate-resistant Prostate Cancer (CRPC) Pipeline Development Activities

The Castrate-resistant Prostate Cancer (CRPC) report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Castrate-resistant Prostate Cancer (CRPC) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Castrate-resistant Prostate Cancer (CRPC) report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Castrate-resistant Prostate Cancer (CRPC) emerging therapies.

Reimbursement Scenario in Castrate-resistant Prostate Cancer (CRPC)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Castrate-resistant Prostate Cancer (CRPC) market trends, we take KOLs and SMEs ' opinion working in the Castrate-resistant Prostate Cancer (CRPC) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Castrate-resistant Prostate Cancer (CRPC) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Castrate-resistant Prostate Cancer (CRPC) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Castrate-resistant Prostate Cancer (CRPC), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Castrate-resistant Prostate Cancer (CRPC) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Castrate-resistant Prostate Cancer (CRPC) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Castrate-resistant Prostate Cancer (CRPC) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Castrate-resistant Prostate Cancer (CRPC) market

Report Highlights

• In the coming years, the Castrate-resistant Prostate Cancer (CRPC) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Castrate-resistant Prostate Cancer (CRPC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Castrate-resistant Prostate Cancer (CRPC). The launch of emerging therapies will significantly impact the Castrate-resistant Prostate Cancer (CRPC) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Castrate-resistant Prostate Cancer (CRPC)
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Castrate-resistant Prostate Cancer (CRPC) Report Insights

• Castrate-resistant Prostate Cancer (CRPC) Patient Population
• Therapeutic Approaches
• Castrate-resistant Prostate Cancer (CRPC) Pipeline Analysis
• Castrate-resistant Prostate Cancer (CRPC) Market Size and Trends
• Castrate-resistant Prostate Cancer (CRPC) Market Opportunities
• Impact of upcoming Castrate-resistant Prostate Cancer (CRPC) Therapies

Castrate-resistant Prostate Cancer (CRPC) Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Castrate-resistant Prostate Cancer (CRPC) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Castrate-resistant Prostate Cancer (CRPC) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Castrate-resistant Prostate Cancer (CRPC) Pipeline Product Profiles
• Castrate-resistant Prostate Cancer (CRPC) Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Castrate-resistant Prostate Cancer (CRPC) drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Castrate-resistant Prostate Cancer (CRPC) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Castrate-resistant Prostate Cancer (CRPC) market size during the forecast period (2019-2032)?
• At what CAGR, the Castrate-resistant Prostate Cancer (CRPC) market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Castrate-resistant Prostate Cancer (CRPC) market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Castrate-resistant Prostate Cancer (CRPC) market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Castrate-resistant Prostate Cancer (CRPC)?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Castrate-resistant Prostate Cancer (CRPC) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Castrate-resistant Prostate Cancer (CRPC) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Castrate-resistant Prostate Cancer (CRPC)?
• Out of all 7MM countries, which country would have the highest prevalent population of Castrate-resistant Prostate Cancer (CRPC) during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Castrate-resistant Prostate Cancer (CRPC) treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Castrate-resistant Prostate Cancer (CRPC) in the USA, Europe, and Japan?
• What are the Castrate-resistant Prostate Cancer (CRPC) marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Castrate-resistant Prostate Cancer (CRPC)?
• How many therapies are in-development by each company for Castrate-resistant Prostate Cancer (CRPC) treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Castrate-resistant Prostate Cancer (CRPC) treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Castrate-resistant Prostate Cancer (CRPC) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Castrate-resistant Prostate Cancer (CRPC) and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Castrate-resistant Prostate Cancer (CRPC)?
• What are the global historical and forecasted market of Castrate-resistant Prostate Cancer (CRPC)?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Castrate-resistant Prostate Cancer (CRPC) market
• To understand the future market competition in the Castrate-resistant Prostate Cancer (CRPC) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Castrate-resistant Prostate Cancer (CRPC) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Castrate-resistant Prostate Cancer (CRPC) market
• To understand the future market competition in the Castrate-resistant Prostate Cancer (CRPC) market

Stay Updated with us for Recent Articles

• PARP inhibitors making inroads towards the first line metastatic Castrate-resistant prostate cancer (CRPC) market soon?
• Latest DelveInsight Blogs